Efficient vitreolysis by combining plasmin and sulfur hexafluoride injection in a preclinical study in rabbit eyes

Wei-Chi Wu,1,2 Chi-Hsien Liu,3 Chih-Chun Chen,4 Nan-Kai Wang,1,2 Kwan-Jen Chen,1,2 Tun-Lu Chen,1,2 Yih-Shiou Hwang,1,2 Lien-Min Li,1 Chi-Chun Lai1,2

1Department of Ophthalmology, Chang Gung Memorial Hospital, Taoyuan, Taiwan; 2Chang Gung University, College of Medicine, Taoyuan, Taiwan; 3Graduate Institute of Biochemical and Biomedical Engineering, Chang Gung University, Taoyuan, Taiwan; 4Microscopy Core Laboratory, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Purpose: To investigate the efficacy of plasmin and sulfur hexafluoride (SF6) on the vitreoretinal junction, as well as the long-term safety in the eye and effect on the recipient’s general health after application in the eye.

Methods: The study design included four groups of rabbits with three animals in each group. Group 1 received an intravitreal injection (IVI) of plasmin and SF6 in the right eye; group 2 received an IVI of plasmin in the right eye; group 3 received an IVI of SF6 in the right eye; and group 4 received an IVI of balanced salt solution in the right eye, which served as a normal control. Long-term safety (up to approximately three months) after plasmin and/or SF6 injection was evaluated morphologically by clinical examination, histology, and immunohistochemistry, and functionally by electroretinograms (ERGs). General health evaluations after intravitreal injection included the assessment of weight gain, food intake, body temperature, and complete blood count analysis.

Results: Plasmin plus SF6 injection resulted in complete posterior vitreous detachment (PVD), whereas plasmin or SF6 injection alone resulted in only partial PVD. Balanced salt solution did not induce PVD. Eighty days after intravitreal injection, there were no major differences among the eyes of the three groups of animals compared with the normal control animals upon clinical evaluation, or regarding retinal morphology and ERGs. The lenses examined remained clear for up to 80 days following the intravitreal injection of plasmin plus SF6, except one eye in the plasmin-treated group. ERGs decreased transiently one week after intravitreal injection in groups 1 through 3, but animals recovered fully to normal status afterward. General health was not affected after the injection of plasmin plus SF6.

Conclusions: Efficient vitreoretinal separation could be achieved, and an acceptable long-term safety profile was noted after plasmin plus SF6 injection in the eye. No major ocular toxicity or systemic toxicity was found after the injection of plasmin plus SF6. These results provide good support for the future clinical use of plasmin plus SF6 for treatment of a variety of vitreoretinopathies.

Vitreous traction on the retina can be a significant pathological factor in certain retinopathies, including central retinal vein occlusion, pediatric vitreoretinopathy, diabetic retinopathy, age-related macular degeneration, and cystoid macular edema [1-7]. Studies have shown that patients with posterior vitreous detachment (PVD), which is characterized by a lack of vitreous traction on the retina, had a better visual prognosis in certain retinopathies such as retinal vessel occlusion and age-related macular degeneration [4,7]. Relief of vitreous traction by the induction of PVD is theoretically helpful for these retinopathies.

Plasmin is a serine protease that mediates the fibrinolytic process and modulates the extracellular matrix [8]. It hydrolyzes a variety of glycoproteins, including laminin and fibronectin, both of which are present at the vitreoretinal interface and are thought to play a key role in vitreoretinal attachment [9,10]. Plasmin enzyme has been proven to cause vitreous liquefaction and PVD [11-17]. Pharmacological vitreolysis with microplasmin, a truncated form of plasmin, increases vitreous diffusion coefficients [18] and oxygen levels in the vitreous [19]. Therefore, plasmin might be useful in treating a variety of retinopathies because it reduces vitreous traction and retinal ischemia.

In cases without cellular attachment in the vitreoretinal junction, plasmin injection could weaken vitreoretinal adhesion and result in PVD. However, in cases with tough vitreoretinal adhesion with a cellular component, plasmin injection alone results in partial PVD [20]. This condition is termed “anomalous PVD,” and is associated with a worse outcome. Therefore, the plasmin enzyme was used clinically, mainly as an adjuvant, to reduce vitreoretinal adhesion during vitrectomy surgery [11-15,21-23]. With the application of a plasmin enzyme, PVD was less traumatic than when mechanical methods alone were used [24]. To increase its efficiency in cleaving vitreoretinal adhesion, Sebag was the first to propose the concept of combination pharmacologic vitreolysis therapy [25]. Combination
therapy could work more effectively than a single agent in conditions characterized by firm vitreoretinal adhesion.

Several animal studies have shown a good safety profile for plasmin when used in the eye [20,26-28]. Most of the studies used plasmin as a single agent to induce PVD and were conducted over short study periods. Very few studies have addressed the combination vitreolysis technique [20,29]. The long-term safety of plasmin combined with other agents in the eyes remains unknown. The purpose of this study was to investigate the long-term effect of plasmin plus sulfur hexafluoride (SF₆) on vitreoretinal adhesion, ocular safety, and the recipient’s general health after application in the eye.

**METHODS**

**Evaluation:** The effect of PVD produced by the plasmin enzyme was investigated by transmission and scanning electron microscopy (TEM and SEM, respectively). The long-term safety profile of an intravitreal plasmin injection was evaluated by examining morphological as well as functional changes in the retina. Clinical examinations included slit lamp examinations, indirect ophthalmoscope, and fundus photos. Morphological studies included retinal histology and immunohistochemistry (IHC) by various antibodies that recognized specific layers of retinal cells. Functional studies of the retina used electroretinograms (ERGs) to identify functional changes in the retina after plasmin injection. An evaluation of general health after intravitreal injection included the assessment of weight gain, food intake, body temperature, and complete blood count (CBC) analysis.

**Animals:** Japanese white rabbits (1.5–1.7 kg) were used in this study. The animals were purchased from the Animal Health Research Institute, Council of Agriculture (Executive Yuan, Jhunan, Taiwan) and were housed in the animal care facilities of the Chang Gung Memorial Hospital, Taoyuan, Taiwan. Animal handling was performed in accordance with the regulations at Chang Gung Memorial Hospital for the use of experimental animals and the Association for Research in Vision and Ophthalmology statement for the use of animals in Ophthalmic and Vision Research. The execution of this project followed the guidelines and standards of Good Laboratory Practice.

**Grouping of the animals and intravitreal injection:** The right eye of each rabbit in group 1 received a pars plana injection of 1 unit of human plasmin (0.1 ml) reconstituted in sterile balanced salt solution (BSS); CalBiochem, La Jolla, CA) plus 0.5 ml of SF₆ in the mid vitreous cavity. The right eye of each rabbit in group 2 received an intravitreal injection of 1 unit of human plasmin (0.1 ml) only. The right eye of each rabbit in group 3 received an intravitreal injection of 0.5 ml of SF₆ only. The left eye of each animal in these three groups received an injection of 0.1 ml BSS.

Animals in group 4 received a BSS injection in the right eye and no injection in the left eye. Each group consisted of three animals. The rabbits were anesthetized with intramuscular injections of 1.5 mL/kg of an equal volumemixture of 2-(2,6-xylidino)-5,6-dihydro-4H-1,3-thiazine-hydrochloride, methylparaben (Rompun; Bayer AG, Leverkusen, Germany) and 50 mg/ml ketamine (Ketomin; Nang Kuang Pharmaceutical Co., Tainan, Taiwan). Topical anesthesia (Alcaine; Alcon-Couvreur, Puurs, Belgium) was administered to reduce the animals’ discomfort [30].

The intravitreal injection was performed 2 mm posterior to the limbus while the eye was being observed under a surgical microscope (M691; Wild Heerbrugg, Heerbrugg, Switzerland), with the help of a prism lens. Care was taken to avoid damage to the lens and the retina during the injection.

**Clinical observations and electrophysiological examination:** Slit-lamp (SL-15; Kowa, Tokyo, Japan) examinations and indirect ophthalmoscopy (Omega 500; Heine, Herrsching, Germany) were performed. The degree of conjunctival congestion was evaluated by the Cornea and Contact Lens Research Unit (CCLRU) grading scale [31]. The severity of conjunctival redness ranged from very slight (grade 1) to slight (grade 2), moderate (grade 3), and severe (grade 4). External photos and color fundus photos were obtained to document the status of the cornea, conjunctiva, lens, vitreous, and retina after plasmin plus or without SF₆ injection. For ERG recordings, the rabbits were anesthetized, their pupils were dilated, and a topical anesthetic was applied to the cornea. After 1 h of dark adaptation, ERGs were recorded with an ERG recording system (RETIpport ERG; Roland Consult, Brandenburg, Germany) at baseline and at 1, 3, 7, 14, 28, and 80 days after the intravitreal injections. ERGs were recorded with a contact lens electrode that contained light-emitting diodes as a stimulator and that was connected to an electrode on the forehead. A ground electrode was attached to the ear. Amplitudes and implicit times of a- and b-waves were evaluated. These protocols have been published previously [30]. The luminance of the stimulus was 3 cd/m², with a duration of 10 ms. Scotopic 0-dB ERGs were recorded with a standard white flash and a dark background. Twenty responses elicited by identical flashes applied at 10-s intervals were averaged in the dark-adapted state.

**Histological and electron microscopic examination:** Eighty days after intravitreal injection, all animals were simultaneously sacrificed by an overdose of anesthetics. After enucleation, the eyes were opened with a razor blade, which was used to penetrate the vitreous adjacent to the pars plana to ensure rapid penetration of the fixative. Care was taken to avoid damage to the adjacent retina and lens. Morphological examinations by histology, SEM, and TEM
were performed in each eye. One third of the retina was sectioned for IHC, one third for SEM examination, and one third for retinal histology and TEM examination. Therefore, each eye was used for all three morphological analyses.

For TEM, after fixation by a mixture of 3% glutaraldehyde and 2% paraformaldehyde, the tissue was dehydrated in an ethanol series, postfixed in 1% osmium tetroxide, and embedded in epoxy resin (Epok 812; Oken, Tokyo, Japan). Sections were stained with 0.5% toluidine blue. Ultrathin sections were stained for contrast with 8% uranyl acetate and lead citrate, and were analyzed using electron microscopy (H7500; Hitachi, Tokyo, Japan). The observers were blinded to group classification when they interpreted the morphological data. SEM was performed to verify the TEM findings.

**Immunohistochemistry with confocal microscopy:** IHC was used to visualize cells in different retinal layers 80 days after intravitreal injection. The integrity of the intermediate filament proteins of Müller cells and rods were verified. A protocol that was published in a previous study was used with modifications [30]. In brief, after the cornea, lens, and vitreous were removed, the eye cup was cut into three pieces, and one of these pieces was used for the IHC study. The retinas were fixed in 4% paraformaldehyde overnight. They were then incubated in 30% sucrose (USB Corp., Cleveland, OH) overnight at 4 °C, embedded in an optimal cutting temperature compound (Sakura Finetek, Torrance, CA), and sectioned with a microtome cryostat (CM3050S; Leica, Wetzlar, Germany). The sections were placed on slides that had been coated with silane (Muto PureChemicals, Tokyo, Japan) to promote adhesion of the sections to the glass surface. Samples were blocked with 1% BSA (in PBS) for 60 min after washing in PBS. After removal of the blocking serum, the following primary antibodies were added: antivimentin (1:1; Dako, Glostrup, Denmark) and antirhodopsin (1:50; Santa Cruz Biotechnology, Santa Cruz, CA). IgG-fluorescein isothiocyanate was used as a secondary antibody. The resulting sections were then viewed under confocal microscopy (TCSSP2; Leica, Wetzlar, Germany).

**Body temperature, food Intake, and weight gain:** Body temperature, food intake, and weight gain were viewed as indicators of general health in the rabbits. Body temperature and food intake were measured on a daily basis, and the weight of each animal was measured at least every 2 weeks and on the day of anesthesia.

**Complete blood count:** Before and after the experiment, a CBC was taken to detect signs of infection, anemia, or abnormalities in the blood. Blood from the ear was collected for analysis.

**Statistical evaluation:** We compared ERG results between the study eyes and the control eyes before and after intravitreal injection and among the different treatment groups. The results among the different groups were compared using ANOVA and the Dunnett post hoc test. The Wilcoxon signed-rank test was used to compare ERG results at baseline and after treatment, as well as to compare results between study eyes and control eyes. Amplitudes and implicated times of the a- and b-waves were analyzed by group mean comparisons. CBC data were compared before and after intravitreal injection and among different treatment groups. p<0.05 was considered statistically significant.

**RESULTS**

**Clinical examinations and electroretinograms:** At 7, 14, 28, and 80 days after intravitreal injection, animals were anesthetized, and external photographs were taken with a digital camera. The degree of conjunctival congestion was assessed by the CCLRU grading scale. Signs of wound infection and corneal epithelial defects were recorded. The degree of conjunctival congestion was similar between the experimental and control eyes. After surgeries, moderate to severe conjunctival congestion lasted for approximately two weeks, after which time the redness decreased gradually. There was no significant difference in the degree of conjunctival redness assessed by the CCLRU grading scale up to 80 days after surgery among these treatment groups. None of these eyes developed corneal or conjunctival infection by the end of the experiment. A mild cellular reaction was noted in the anterior chamber after intravitreal injection of plasmin plus or without SF6, but the reaction cleared in all eyes within one week. The lens remained clear up to 80 days following the intravitreal injection of plasmin plus SF6, except one eye in the plasmin-treated group. Dilated fundus examinations revealed no signs of vitreous opacity, retinal detachment, vessel occlusion, or retinal necrosis in any animal (Figure 1). ERG data showed a transient decrease in a- and b-wave amplitude within one week after the injections in groups 1, 2, and 3. At one week after the injections, the amplitude returned to baseline. Representative ERG b-wave changes are shown in Figure 2.

**Histology of the retina:** There were no noticeable differences in the histology of the retina among the three treatment groups by the end of this study (Figure 3). The retinal morphology of plasmin plus or without SF6–treated eyes was similar to that of the control eyes. Some vacuole changes could be seen in all groups of animals, even in the normal control group. However, no significant morphological changes, including retinal structure deformation, thinning, or retinal layer loss, were seen in a specific group of animals. Therefore, such morphological changes may have been associated with the tissue handling or the normal physiologic apoptosis or aging changes of the retina.

TEM was used to investigate the presence of vitreoretinal adhesion and to characterize the ultramorphology in different retinal layers after plasmin plus...
or without SF₆ treatment. Dense collagen fibrils were still attached to the internal limiting membrane (ILM) in the control eyes. In contrast, eyes treated with plasmin or SF₆ alone showed a cleaner ILM with limited adhesion of collagen fibrils. Eyes treated with plasmin plus SF₆ were free from adhesion of collagen fibrils (Figure 4). These results showed that BSS-treated eyes did not undergo PVD. Partial PVD was observed in the plasmin injection group (group 2) and the group receiving the long-acting gas, sulfur hexafluoride (group 3). However, the plasmin enzyme plus the long-acting SF₆ gas (group 1) produced complete PVD.

The ultrastructure in the retinal pigment epithelium, the outer segments of photoreceptors, the inner segments of photoreceptors, the mitochondria in the inner segments, and cells in the outer nuclear layer showed normal morphology.
in all four treated groups. SEM and TEM findings were consistent.

**Immunohistochemistry:** IHC using antibodies that recognized different layers of cells in the retina was performed to compare the difference between treated and control eyes. We did not find any major differences in the IHC results, indicating that the specific cells within the retina were not affected by plasmin plus or without SF₆ treatment (Figure 5).

**Body temperature, food intake, weight gain, and complete blood count:** We did not find any differences in body temperature, food intake, or weight gain among rabbits receiving plasmin plus SF₆, plasmin alone, or SF₆ alone. There were no major differences in the CBC before and after intravitreal injection among the three groups of animals (data not shown).

**DISCUSSION**

It is important to assess the long-term safety of plasmin plus SF₆, including ocular safety and systemic safety, before beginning the clinical application of these agents. Our data also showed good efficacy of PVD induction by plasmin plus SF₆. Our clinical observations, as well as our morphological and functional studies on the eye, revealed good safety profiles of plasmin plus the long-acting gas SF₆ when injected into the eye. The rabbits’ general health was not affected by the injection of plasmin plus SF₆. This study has provided important preclinical information regarding the application of plasmin plus SF₆ in treating a variety of retinopathies.

Plasmin plus other agents or surgery is necessary to produce a complete PVD in clinical situations with tight vitreoretinal adhesion. In the clinical trial of vitreomacular
adhesion treated with intravitreal microplasmin (ThromboGenics Ltd., Dublin, Ireland), a truncated form of plasmin, PVD occurred 8% to 44% of the time, depending on the dose of microplasmin used [32]. Repeated injection of microplasmin (up to three times) increased the incidence of PVD to 58% [32]. These data suggest that even with the use of plasmin and after multiple enzyme injections, the induction of PVD did not reach 100%. However, the
plasmin enzyme alone could not produce a complete PVD in some retinal disorders with firm vitreoretinal adhesion, such as diabetic retinopathy [20]. Plasmin injection alone in diabetic retinopathy weakens the vitreoretinal adhesion and most often results in partial PVD only, which is an even more dangerous situation with a worsened clinical outcome [33,34]. Additional procedures, such as vitrectomy or the combination of other agents, are needed to induce a complete PVD in retinopathy with prominent cellular proliferation and attachment of the vitreoretinal junction. SF$_6$ injection alone has been shown to induce PVD clinically [35,36]. Combining plasmin with the long-acting gas SF$_6$ might be more effective in cases with particularly strong vitreoretinal adhesion and may induce a complete vitreoretinal separation, unlike that achieved by the use of a single agent. In addition, this procedure is less aggressive than combining plasmin and vitrectomy.

Although the half-life of plasmin is short, its effect could last for long time. For instance, cataract formation might not be visible immediately after the injection of plasmin, but may appear later. Therefore, the long-term effect is important if we are going to use plasmin and SF$_6$ to treat a variety of vitreoretinopathies with tougher vitreoretinal adhesion in the future. Hikichi et al. [29] was the first to use plasmin and SF$_6$ to induce PVD in rabbit eyes. They found effective PVD induction after the use of plasmin combined with SF$_6$. They observed a short-term effect of combined vitreolysis by plasmin and SF$_6$ up to seven days; we extended the follow-up to almost three months. In addition to ocular safety evaluation, we added the evaluation of systemic safety. Our findings suggest the potential of combining plasmin and SF$_6$ because of the desired clinical effect and good safety profile associated with such treatment.

In the current study, we observed transient ERG changes following the injection of plasmin. After one week, the ERG returned to normal baseline levels. We hypothesize that this phenomenon is associated with the pressure changes following intravitreal injection. The pressure changes might be related to the properties and the volume of the agents injected into the vitreous. We noted mild transient inflammation after the injection of plasmin into the rabbit eyes. The intraocular pressure was high immediately after intravitreal injection, but gradually returned to normal [37]. This indicates that the agents injected into the vitreous caused transient photoreceptor dysfunction, but the ERG values returned to pretreatment levels shortly after the injection. Eyes in group 4 received the lowest injected volume of all the groups and BSS did not cause an inflammatory reaction after its injection in the eyes. These two factors could contribute to the lack of ERG changes after intravitreal injection in these animals. Transient and mild inflammation could be encountered following the injection of plasmin plus or without SF$_6$. Cataracts could also arise following intravitreal injection of plasmin, although the incidence is not high. This result could be
attributed to the intravitreal injection or the effect of plasmin on the lens. The combination of plasmin plus SF₆ seems to be well tolerated in the eye and was not associated with increased complications. Yet, our study is limited by the small number of animals used. No definite conclusions could be drawn, although the initial results are promising.

Notably, the PVD effect produced by plasmin is dose and time dependent [38]. In the clinical trial of vitreomacular traction syndrome treated with microplasmin, increased exposure and doses augmented the incidence of PVD induction [39]. Therefore, sufficient doses of plasmin and time for action are required to produce the complete effect of vitreoretinal separation. Insufficient doses or time for action will produce either no separation at all or only partial vitreoretinal separation, a condition that is associated with poor prognoses, as mentioned above.

Figure 5. Representative images from immunohistochemistry 80 days after intravitreal injection of plasmin and SF₆ (group 1), plasmin (group 2), SF₆ (group 3), or balanced salt solution (control group). There were no significant differences in the retinal cell components between eyes receiving plasmin and/or SF₆ and balanced salt solution (BSS). The scale bar represents 150 μm.
In conclusion, our results suggest an efficient vitreoretinal separation and a good long-term safety profile for plasmin plus SF₆ injection into the eye. No major systemic toxicity was found after the injection of plasmin plus SF₆. These results provide support for the future clinical use of plasmin plus SF₆ to treat a variety of vitreoretinopathies with tougher vitreoretinal adhesion.

ACKNOWLEDGMENTS

The study was supported by the Chang Gung Memorial Hospital Research Grants, Linkou, Taiwan CMRPG3A0391 and CMRPG3A0392. The study was helped by the Microscope Core Laboratory, Chang Gung Memorial Hospital, Linkou and the Laboratory Animal Center, Chang Gung Memorial Hospital, Linkou.

REFERENCES

1. Schepens CL, Avila MP, Jalkh AE, Trempe CL. Role of the vitreous in cystoid macular edema. Surv Ophthalmol 1984; 28:499-504. [PMID: 6463849]
2. Machemer R. Description and pathogenesis of late stages of retinopathy of prematurity. Ophthalmology 1985; 92:1000-4. [PMID: 2413414]
3. Tagawa H, McMeel JW, Furukawa H, Quiroz H, Murakami K, Takahashi M, Trempe CL. Role of the vitreous in diabetic retinopathy. I. Vitreous changes in diabetic retinopathy and in physiologic aging. Ophthalmology 1986; 93:596-601. [PMID: 3725319]
4. Robison CD, Krebs I, Binder S, Barbazetto IA, Kotsolis AI, McMeel JW, Schepens CL. The role of the vitreous in diabetic macular edema. Ophthalmology 1988; 95:1335-9. [PMID: 3226682]
5. Nasrallah FP, Jalkh AE, Van Coppenolle F, Kado M, Trempe CL, McMeel JW, Schepens CL. The role of the vitreous in diabetic macular edema. Surv Ophthalmol 2000; 44:79-82. [PMID: 19327744]
6. Joshi MM, Ciaccia S, Trese MT, Capone A Jr. Posterior hyaloid contracture in pediatric vitreoretinopathies. Retina 2006; 26:S38-41. [PMID: 16946676]
7. Hikichi T, Konno S, Trempe CL. Role of the vitreous in central retinal vein occlusion. Retina 1995; 15:29-33. [PMID: 7754244]
8. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collageenous components of basement membrane. Cancer Res 1981; 41:4629-36. [PMID: 6458354]
9. Kohno T, Sorgente N, Ishibashi T, Goodnight R, Ryan SJ. Immunofluorescent studies of fibronectin and laminin in the human eye. Invest Ophthalmol Vis Sci 1987; 28:506-14. [PMID: 3549611]
10. Russell SR, Shepherd JD, Hageman GS. Distribution of glycoconjugates in the human retinal internal limiting membrane. Invest Ophthalmol Vis Sci 1991; 32:1986-95. [PMID: 2055693]
11. Wu WC, Drenser KA, Lai M, Capone A, Trese MT. Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity. Retina 2008; 28:S75-80. [PMID: 18317350]
12. Wu WC, Drenser KA, Trese MT, Williams GA, Capone A. Pediatric traumatic macular hole: results of autologous plasmin enzyme-assisted vitrectomy. Am J Ophthalmol 2007; 144:668-72. [PMID: 17870044]
13. Wu WC, Drenser KA, Capone A, Williams GA, Trese MT. Plasmin enzyme-assisted vitrectomy in congenital X-linked retinoschisis: surgical techniques based on a new classification system. Retina 2007; 27:1079-85. [PMID: 18040249]
14. Williams JG, Trese MT, Williams GA, Hartzker MK. Autologous plasmin enzyme in the surgical management of diabetic retinopathy. Ophthalmology 2001; 108:1902-5. [PMID: 11581070]
15. Tsukahara Y, Honda S, Imai H, Kondo N, Fuji S, Yokoyama N, Hirata A, Kawai T, Fukushima M, Tanihara H, Negi A. Autologous plasmin-assisted vitrectomy for stage 5 retinopathy of prematurity: a preliminary trial. Am J Ophthalmol 2007; 144:139-41. [PMID: 17601440]
16. Trese MT, Williams GA, Hartzker MK. A new approach to stage 3 macular holes. Ophthalmology 2000; 107:1607-11. [PMID: 10919918]
17. Diaz-Llopis M, Uadoono P, Arevalo F, Salom D, Garcia-Delpech S, Quijada A, Romero FJ. Intravitreal plasmin without associated vitrectomy as a treatment for refractory diabetic macular edema. J Ocul Pharmacol Ther 2009; 25:379-84. [PMID: 19650710]
18. Sebag J, Ansari RR, Suh KI. Pharmacologic vitreolysis with microplasmin increases vitreous diffusion coefficients. Graefes Arch Clin Exp Ophthalmol 2007; 245:576-80. [PMID: 16941141]
19. Quiram PA, Leverenz VR, Baker RM, Dang L, Giblin FJ, Trese MT. Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels. Retina 2007; 27:1090-6. [PMID: 18040251]
20. Zhi-Liang W, Wo-Dong S, Min L, Xiao-Ping B, Jin J. Pharmacologic vitreolysis with plasmin and hyaluronidase in diabetic rats. Retina 2009; 29:269-74. [PMID: 19050667]
21. Hirata A, Takano A, Inomata Y, Yonemura N, Sagarac N, Tanihara H. Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study. Retina 2007; 27:1074-8. [PMID: 18040248]
22. Rizzo S, Pellegrini G, Benocci F, Belting C, Baicchi U, Vispi M. Autologous plasmin for pharmacologic vitreolysis prepared 1 hour before surgery. Retina 2006; 26:792-6. [PMID: 16963853]
23. Azzolini C, D’Angelo A, Maestranzi G, Codenotti M, Della Valle P, Prati M, Brancato R. Intravitreal plasmin in diabetic macular edema. Am J Ophthalmol 2004; 138:560-6. [PMID: 15488781]
24. Russell SR, Hageman GS. Optic disc, foveal, and extrafoveal damage due to surgical separation of the vitreous. Arch Ophthalmol 2001; 119:1653-8. [PMID: 11709016]
25. Sebag J. Is pharmacologic vitreolysis brewing? Retina 2002; 22:1-3. [PMID: 11884870]
26. Verstraeten TC, Chapman C, Hartzker M, Winkler BS, Trese MT, Williams GA. Pharmacologic induction of posterior vitreous detachment in the rabbit. Arch Ophthalmol 1993; 111:849-54. [PMID: 8512489]
27. Proksch JW, Driot JY, Vandenbogaard P, Ward KW. Nonclinical safety and pharmacokinetics of intravitreally administered...
human-derived plasmin in rabbits and minipigs. J Ocul Pharmacol Ther 2008; 24:320-32. [PMID: 18476803]
28. Hermel M, Mahgoub M, Youssef T, Azrak MI, Raza H, Allredge C, Trese M, Williams GA, Hartzer M. Safety profile of the intravitreal streptokinase-plasmin complex as an adjunct to vitrectomy in the rabbit. Graefes Arch Clin Exp Ophthalmol 2006; 244:996-1002. [PMID: 16365737]
29. Hikichi T, Yanagiya N, Kado M, Akiba J, Yoshida A. Posterior vitreous detachment induced by injection of plasmin and sulfur hexafluoride in the rabbit vitreous. Retina 1999; 19:55-8. [PMID: 10048374]
30. Wu WC, Lai CC, Chen KJ, Chen TL, Wang NK, Hwang YS, Yeung L, Li LM. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes. Invest Ophthalmol Vis Sci 2010; 51:3701-8. [PMID: 20181842]
31. Cornea and Contact Lenses Research Unit. CCLRU grading scales. Sydney, Australia: University of New South Wales 1996.
32. Stalmans P, Delaey C, de Smet MD, van DE, Pakola S. Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial). Retina 2010; 30:1122-7. [PMID: 20616687]
33. Jalikh A, Takahashi M, Topilow HW, Trempe CL, McMeel JW. Prognostic value of vitreous findings in diabetic retinopathy. Arch Ophthalmol 1982; 100:432-4. [PMID: 7199900]
34. Akiba J, Arzabe CW, Trempe CL. Posterior vitreous detachment and neovascularization in diabetic retinopathy. Ophthalmology 1990; 97:889-91. [PMID: 2381702]
35. Park SW, Seo MS. Subhyaloid hemorrhage treated with SF6 gas injection. Ophthalmic Surg Lasers Imaging 2004; 35:335-7. [PMID: 15305560]
36. Ochoa-Contreras D, Delsol-Coronado L, Buitrago ME, Velasco-Barona C, Quiroz-Mercado H. Induced posterior vitreous detachment by intravitreal sulfur hexafluoride (SF6) injection in patients with nonproliferative diabetic retinopathy. Acta Ophthalmol Scand 2000; 78:687-8. [PMID: 11167234]
37. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina 2007; 27:1044-7. [PMID: 18040242]
38. Gandorfer A, Putz E, Welge-Lussen U, Gruterich M, Ulbig M, Kampik A. Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy. Br J Ophthalmol 2001; 85:6-10. [PMID: 11133703]
39. de Smet MD, Gandorfer A, Stalmans P, Veckeneer M, Feron E, Pakola S, Kampik A. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology 2009; 116:1349-55. [PMID: 19447497]